Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 4/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | NR1D1 | P20393 | 5/20 | 0.39 |
| ▸ | BCL2 | P10415 | 11/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12044649 | 1.00 | PDE9A (0.61) | PDE9APDE5ANR1D1BCL2 | |
| SCHEMBL7912426 | 0.87 | PDE9A (0.70) | PDE9APDE5A | |
| SCHEMBL9979334 | 0.86 | PDE9A (0.42) | PDE9ANR1D1BCL2 | |
| SCHEMBL14826781 | 0.84 | PDE9A (0.63) | PDE9APDE5A | |
| SCHEMBL7902967 | 0.83 | PDE9A (0.42) | PDE9APDE5ABCL2 | |
| SCHEMBL7904294 | 0.83 | PDE9A (0.42) | PDE9APDE5ABCL2 | |
| SCHEMBL3597945 | 0.79 | PDE9A (0.75) | PDE9APDE5A | |
| SCHEMBL3599979 | 0.79 | PDE9A (0.75) | PDE9APDE5A | |
| SCHEMBL12044771 | 0.79 | PDE9A (0.58) | PDE9APDE5A | |
| SCHEMBL3605995 | 0.79 | PDE9A (0.81) | PDE9APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404922-A1 | QUINOXALINE COMPOUNDS | Astellas Pharma Inc. (JP) | 2012-01-11 | — | — | EP | claimed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | claimed |
| EP-2404922-B1 | QUINOXALINE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2016-11-09 | — | — | EP | disclosed |
| US-8674096-B2 | Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE5A 4/4885NR1D1 3508/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | PDE9A 1/4885PDE5A 2/4885NR1D1 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.